SAB Biotherapeutics (SABS) Net Income towards Common Stockholders (2020 - 2026)
SAB Biotherapeutics' Net Income towards Common Stockholders was -$22.49 million in Q2 2026, compared with -$10.11 million a year earlier.
Powered by 
Analysis
SAB Biotherapeutics (SABS) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
On a trailing twelve-month basis, SAB Biotherapeutics' Net Income towards Common Stockholders was -$12.78 million through Jun 30, 2026; for FY2025, it was $13.27 million.
- Net Income towards Common Stockholders shows a five-year compound annual growth rate of -8.0% (FY2020 to FY2025).
- In earlier years, Net Income towards Common Stockholders was -$34.11 million in FY2024, -$42.19 million in FY2023, -$18.74 million in FY2022 and -$17.14 million in FY2021.
- The Q2 2026 figure marks the lowest quarterly Net Income towards Common Stockholders since Q4 2023.
- Per Business Quant data, SABS's Net Income towards Common Stockholders in the three quarters before Q2 2026 was -$18.87 million (Q1 2026), -$16.86 million (Q4 2025) and $45.45 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | -248.00 Mn |
| 10 | SAB Biotherapeutics | 237.12 Mn | -180.38 Mn | - | -22.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.49 Mn |
| Mar 31, 2026 | -18.87 Mn |
| Dec 31, 2025 | -16.86 Mn |
| Sep 30, 2025 | 45.45 Mn |
| Jun 30, 2025 | -10.11 Mn |
| Mar 31, 2025 | -5.20 Mn |
| Dec 31, 2024 | -11.39 Mn |
| Sep 30, 2024 | -10.35 Mn |
| Jun 30, 2024 | -7.34 Mn |
| Mar 31, 2024 | -5.03 Mn |
| Dec 31, 2023 | -22.86 Mn |
| Sep 30, 2023 | -5.10 Mn |
| Jun 30, 2023 | -6.88 Mn |
| Mar 31, 2023 | -7.35 Mn |
| Dec 31, 2022 | -7.87 Mn |
| Sep 30, 2022 | -7.08 Mn |
| Jun 30, 2022 | -4.78 Mn |
| Mar 31, 2022 | 985,863.00 |
| Dec 31, 2021 | -11.55 Mn |
| Sep 30, 2021 | -4.06 Mn |
API Access
SAB Biotherapeutics Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=SABS&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "SABS", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=SABS&period=max&api_key=YOUR_API_KEY");
const data = await res.json();